Balaglitazone
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Balaglitazone是过氧化物酶体增殖物激活受体(PPAR)γ的部分激动剂[1]。
PPAR在调节胰岛素、甘油三酯和脂质代谢中起着重要的作用,是治疗2型糖尿病的一个有吸引力的靶标。Balaglitazone是PPARγ的部分激动剂。Balaglitazone对PPARγ活性具有52%的最大抑制,副作用有所降低。它在各种动物模型表现出强效降血糖的作用[1,2]。
在转染融合PPARγ的HEK293细胞中,基于细胞进行测定,balaglitazone显示出活化乙状结肠的作用,EC50值为1.35 μM。当与罗格列酮(rosiglitazone)组合使用,balaglitazone逐渐增加浓度导致罗格列酮的活性降低到100 nM balaglitazone单独使用时的水平[3]。
在成年雄性糖尿病小鼠中,与罗格列酮相比,增加balaglitazone的口服剂量表现出更有效的降血糖效果。Balaglitazone也造成体液和脂肪积累的减少,且没有心脏扩大,表明它对心血管系统有更高的安全性。除此之外,持续21天施加balaglitazone对于血液或血浆的体积没有显著影响。使用10 mg/kg balaglitazone对骨形成没有影响,这意味着它只是一个部分激动剂,并不能导致骨损失[1,2]。
参考文献:
[1] Agrawal R, Jain P, Dikshit SN. Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist. Mini Rev Med Chem. 2012 Feb;12(2):87-97.
[2] Henriksen K, Byrjalsen I, Nielsen RH, Madsen AN, Larsen LK, Christiansen C, Beck-Nielsen H, Karsdal MA. A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Eur J Pharmacol. 2009 Aug 15;616(1-3):340-5.
[3] Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. Eur J Pharmacol. 2008 Oct 31;596(1-3):173-9
.Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 395.43 |
Cas No. | 199113-98-9 |
Formula | C20H17N3O4S |
Synonyms | DRF-2593;NN-2344;DRF2593;NN2344;DRF 2593;NN 2344 |
Solubility | insoluble in H2O; ≥15.45 mg/mL in DMSO; ≥2.18 mg/mL in EtOH with gentle warming and ultrasonic |
Chemical Name | 5-(4-((3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)methoxy)benzyl)thiazolidine-2,4-dione |
SDF | Download SDF |
Canonical SMILES | O=C1C2=CC=CC=C2N=C(COC3=CC=C(CC4C(NC(S4)=O)=O)C=C3)N1C |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
描述 | Balaglitazone(DRF-2593; NN-2344)是一种新型的PPAR-γ部分激动剂。 | |||||
靶点 | PPARγ | |||||
IC50 |
质量控制和MSDS
- 批次: